But in some cases, tumor infiltrated lymphocytes (TILs) are associated with distinct survival rate after neoadjuvant chemotherapy, e.g. better survival in HER2-positive breast cancer and triple-negative breast cancer (TNBC), but worse survival in luminal–HER2-negative breast cancer (129), (Table 3). The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.